Fig. 2

β-Elemene inhibited hyperactive ILK/Akt pathway in PHAGF through ILK. a RT-qPCR analysis of the ILK/Akt pathway-related mRNA expression in PHAF, PHAGF and β-elemene-treated PHAGF; b, c Western blotting analysis of the ILK/Akt pathway-related proteins’ expression in PHAF, PHAGF and β-elemene-treated PHAGF; ^*P < 0.05, ^**P < 0.01, versus the PHAF group; ^#P < 0.05, ^##P < 0.01, versus the PHAGF + DMSO group (solvent control). d RT-qPCR detection of the transfection efficiency of pcDNA3.1-ILK and to detect the effects of pcDNA3.1-ILK or the pathway inhibitor QLT0267 on expression of ILK/Akt pathway-related mRNAs; e, f Western blotting detection of the ILK/Akt pathway-related protein expression after ILK over-expression or adding the pathway inhibitor QLT0267 in the presence of β-elemene. ^*P < 0.05, ^**P < 0.01, versus the PHAGF + DMSO group; ^#P < 0.05, ^##P < 0.01, versus the β-elemene + pcDNA3.1-NC group; N = no significance, versus the β-elemene group